Moderna, Inc. (MRNA)
- Previous Close
102.00 - Open
102.37 - Bid 100.72 x 100
- Ask 100.95 x 300
- Day's Range
100.45 - 103.79 - 52 Week Range
62.55 - 142.82 - Volume
1,797,191 - Avg. Volume
3,775,035 - Market Cap (intraday)
38.621B - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-12.33 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
132.36
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA
Performance Overview: MRNA
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA
Valuation Measures
Market Cap
39.05B
Enterprise Value
31.69B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.77
Price/Book (mrq)
2.82
Enterprise Value/Revenue
4.69
Enterprise Value/EBITDA
-9.65
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.84%
Return on Assets (ttm)
-11.96%
Return on Equity (ttm)
-28.59%
Revenue (ttm)
6.85B
Net Income Avi to Common (ttm)
-4.71B
Diluted EPS (ttm)
-12.33
Balance Sheet and Cash Flow
Total Cash (mrq)
8.6B
Total Debt/Equity (mrq)
8.97%
Levered Free Cash Flow (ttm)
-2.38B
Research Analysis: MRNA
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: MRNA
Mid Cap U.S. Pick List March 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Analyst Report: Moderna Inc
Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 5,150 employees.
RatingBullishPrice TargetMarket Digest: ALL, DPZ, ED, INTU, VMC, MRNA
As stock prices continue to rise and the valuation band for stocks is stretched further, insider-sentiment data from Vickers Stock Research continues to show that corporate executives, directors, and beneficial owners are increasingly defensive. Is it time to run for exits? Likely no. But stock prices won't go up forever, so a sense of caution does seem to be warranted. And that is what insiders are clearly telling us.
Analyst Report: Moderna, Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingBullishPrice Target